Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Octreotide LAR Clear all
Terminated Phase 2 Interventional Results available

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

NCT01886287
View directory record Official record
Conditions
Neuroendocrine Carcinoma
Interventions
Octreotide LAR
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Oct 17, 2026, 10:08 PM EDT
Completed Phase 4 Interventional Results available

Ultrasound Guided Octreotide LAR Injection in Acromegaly

NCT00552071
View directory record Official record
Conditions
Acromegaly
Interventions
Octreotide LAR 30 MG Injection
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 17, 2026, 10:08 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

NCT00569127
View directory record Official record
Conditions
Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate, Recombinant Interferon Alfa-2b
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
493
States / cities
Mobile, Alabama • Fairbanks, Alaska • Fort Smith, Arkansas + 321 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 17, 2026, 10:08 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

NCT06784752
View directory record Official record
Conditions
Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Interventions
[177Lu]Lu-DOTA-TATE, Octreotide LAR
Radiation · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
20
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 17, 2026, 10:08 PM EDT
Terminated Phase 3 Interventional

Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

NCT00642421
View directory record Official record
Conditions
Acromegaly
Interventions
C2L-OCT-01 PR, 10 or 20 mg, C2L-OCT-01 PR, 20 mg
Drug
Lead sponsor
Ambrilia Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Stanford, California • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2010 · Synced Oct 17, 2026, 10:08 PM EDT
Terminated Phase 3 Interventional

Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

NCT00006269
View directory record Official record
Conditions
Colorectal Cancer, Diarrhea
Interventions
irinotecan hydrochloride, octreotide acetate
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
East Hanover, New Jersey • Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2012 · Synced Oct 17, 2026, 10:08 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors

NCT00590343
View directory record Official record
Conditions
Metastatic Neuroendocrine Tumors
Interventions
vatalanib
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Kenner, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Oct 17, 2026, 10:08 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

NCT00600886
View directory record Official record
Conditions
Acromegaly
Interventions
Pasireotide, Octreotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
14
States / cities
Los Angeles, California • Stanford, California • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 10:08 PM EDT
Completed Phase 3 Interventional

Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer

NCT00002967
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, doxorubicin hydrochloride, octreotide pamoate, tamoxifen citrate
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
106
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 87 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 17, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Results available

Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients

NCT02916433
View directory record Official record
Conditions
Octreotide, Sputum
Interventions
Octreotide
Drug
Lead sponsor
Danbury Hospital
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Danbury, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 17, 2026, 10:08 PM EDT
Completed Phase 4 Interventional

STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea

NCT00050635
View directory record Official record
Conditions
Neoplasms, Diarrhea
Interventions
Sandostatin LAR Depot
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
34
States / cities
Burbank, California • Concord, California • Fountain Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2009 · Synced Oct 17, 2026, 10:08 PM EDT
Completed Phase 4 Interventional

Pediatric Hypothalamic Obesity

NCT00076362
View directory record Official record
Conditions
Obesity
Interventions
Sandostatin LAR
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
15
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 17, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Results available

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

NCT00853047
View directory record Official record
Conditions
Carcinoid Syndrome
Interventions
Telotristat etiprate, Octreotide LAR Depot, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
9
States / cities
Little Rock, Arkansas • San Francisco, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 17, 2026, 10:08 PM EDT
Completed Phase 3 Interventional

Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer

NCT00002864
View directory record Official record
Conditions
Breast Cancer
Interventions
octreotide acetate, tamoxifen citrate
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
Up to 120 Years · Female only
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2010
U.S. locations
2
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 17, 2026, 10:08 PM EDT
Terminated Phase 2 Interventional Results available

Sandostatin for Patients With Androgen Independent Prostate Cancer

NCT00510224
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sandostatin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 17, 2026, 10:08 PM EDT
Completed Phase 4 Interventional Results available

Surgical Debulking of Pituitary Adenomas

NCT01371643
View directory record Official record
Conditions
Pituitary Adenoma
Interventions
Octreotide LAR, transsphenoidal surgery
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Oct 17, 2026, 10:08 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

NCT01578239
View directory record Official record
Conditions
Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour
Interventions
Octreotide LAR, 177Lu-DOTA0-Tyr3-Octreotate
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 17, 2026, 10:08 PM EDT
Completed Phase 2 Interventional

Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma

NCT00250796
View directory record Official record
Conditions
Liver, Cancer
Interventions
Thalidomide, alpha interferon, Thalidomide, interferon, Octreotide
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
2
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 7, 2010 · Synced Oct 17, 2026, 10:08 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

NCT03972488
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution, High dose 60 mg octreotide long-acting repeatable
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 17, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)

NCT03792555
View directory record Official record
Conditions
Acromegaly
Interventions
Paltusotine, Placebo
Drug
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Columbus, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 17, 2026, 10:08 PM EDT
Terminated Phase 3 Interventional

Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

NCT00765323
View directory record Official record
Conditions
Acromegaly
Interventions
Octreotide Implant, Sandostatin LAR Depot
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
Palo Alto, California • Denver, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2013 · Synced Oct 17, 2026, 10:08 PM EDT
Completed Phase 3 Interventional

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

NCT00075868
View directory record Official record
Conditions
Anal Cancer, Colorectal Cancer, Drug/Agent Toxicity by Tissue/Organ, Radiation Enteritis
Interventions
octreotide acetate, Placebo
Drug · Other
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
112
States / cities
Mobile, Alabama • Phoenix, Arizona • Chico, California + 89 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 17, 2026, 10:08 PM EDT
Completed Phase 1 Interventional

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

NCT01204476
View directory record Official record
Conditions
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Paraganglioma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Merkel Cell Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor, Stage III Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma, Thyroid Gland Medullary Carcinoma
Interventions
Cixutumumab, Everolimus, Laboratory Biomarker Analysis, Octreotide Acetate, Pharmacological Study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 17, 2026, 10:08 PM EDT
Terminated Phase 2 Interventional

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

NCT01469338
View directory record Official record
Conditions
Diarrhea, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
cabazitaxel, prednisone, octreotide pamoate, questionnaire administration, octreotide acetate
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 17, 2026, 10:08 PM EDT